Cardiac biomarkers are used in the diagnosis and risk stratification of patients with chest pain and suspected acute coronary syndrome (ACS).
In patients with ACS, cardiac ischemia and other heart conditions associated with insufficient blood flow to the heart, these biomarkers are absolutely critical indicators to determine if a paitent is experiencing an acute miocaridial infraction (MI) or heart attack.
RYVEX understands the need for reliable, robust and efficient testing and have added the following to our portfolio:
